[PSY74] Cost–Utility Analysis of Antihemophilic Factor Rfviii-Fs for Secondary Prophylaxis Vs on-Demand Therapy In Severe Haemophilia A In Italy

[PSY74] Cost–Utility Analysis of Antihemophilic Factor Rfviii-Fs for Secondary Prophylaxis Vs on-Demand Therapy In Severe Haemophilia A In Italy

2015 Value in Health

Tagliaferri, A. | Coppola, A. | Amoresano, S. | Aiello, A. | D’Ausilio, A. | Toumi, M. | Volume: 18, Issue: 7, Pages: A671,

Haemophilia A causes a considerable burden on society. While prophylaxis in children aged ≤2y is now a gold standard treatment, the benefits of late secondary prophylaxis are still controversial. Aim of this study is to estimate the cost-utility of antihemophilic factor rFVIII-FS (Kogenate® FS) in secondary prophylaxis vs on-demand regimen from the Italian healthcare system (NHS) and society perspective.

https://www.doi.org/10.1016/j.jval.2015.09.1974